Genenta Secures €20M, Brain Tumor Trial Shows Promising Survival
Genenta Science secured €20 million (approximately $21.9 million) in financing from ENEA Tech and Biomedical (ETB) to support the...
eClinical Tech News
Savolitinib Shines in HutchMed Phase II Lung Cancer Trial
HUTCHMED announced new data from studies of savolitinib and surufatinib, two compounds it discovered, will be presented at the...
Protara Therapeutics: Choline Deficiency and Liver Injury in Parenteral Support Patients: Encore Presentation of THRIVE-1 Results
Protara Therapeutics announced results from THRIVE-1, a study on choline deficiency and liver injury in patients dependent on parenteral...
Acumen Announces Results for Sabirnetug Formulation Study
Acumen Pharmaceuticals announced positive topline results from a Phase 1 study of its Alzheimer’s drug, sabirnetug. The study compared...
Arbor Biotechnologies Secures $73.9M Series C Funding for Gene Editing
Arbor Biotechnologies secured $73.9 million in Series C funding, led by ARCH Venture Partners and TCGX, to advance its...
Fruquintinib & Sintilimab Trial Meets Primary Endpoint in Advanced RCC
HUTCHMED and Innovent Biologics announced positive top-line results from the FRUSICA-2 Phase II/III trial. The trial investigated fruquintinib combined...
Ocu200 DME Trial: Cohort 2 Dosing Approved After Safety Review
Ocugen, a biotechnology company, announced positive safety data from the first cohort of its Phase 1 clinical trial for...
Clearmind Medicine Initiates First Human Trial for Alcohol Use Disorder
Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a novel psychedelic-derived treatment for Alcohol Use...
Angitia Biopharmaceuticals Presents Promising Phase 1/2 Study Data of AGA111 at AAOS
Angitia Biopharmaceuticals announced positive Phase 1/2 trial data for AGA111, a recombinant human bone morphogenetic protein 6 (rhBMP6) designed...
Prime Medicine Unveils AATD Gene Correction Treatment Program
Prime Medicine announced a preclinical program for alpha-1 antitrypsin deficiency (AATD), using its prime editing technology delivered via a...